Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04903795 · ClinicalTrials.gov registry record · Phase 1
BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
A Phase 1 study, sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP.
- Not yet
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04903795: Clinical Trial Phase 1 study, sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP.
NCT04903795 is a Phase 1 study that has not yet begun recruiting, run by Mustafa Khasraw, MBChB, MD, FRCP, FRACP. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04903795, a Phase 1 study, has not yet begun recruiting, sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This Phase 1 study will assess the safety of a novel brain Bispecific T cell engager (BRiTE) in patients with newly diagnosed or recurrent World Health Organization (WHO) Grade 4 glioblastoma (GBM). Owing to its short half-life, the study drug, BRiTE, will be continuously infused intravenously (IV) for 4 days (96 hours) in a 28-day cycle. Given that BRiTE specifically exerts its effects on tumor cells expressing the Epidermal Growth Factor Receptor variant III (EGFRvIII) mutation, we will only enroll patients with EGFRvIII-positive tumors in this study. The primary objective is to evaluate the safety and tolerability of continually infused BRiTE in ndGBM and rGBM patients and determine the maximum tolerated dose (MTD) for continuously infused BRiTE.
Primary Outcome
Proportion of patients with DLT within each dose level
Interventions
- DRUG hEGFRvIII-CD3 (BRiTE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-08 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What is known before NCT04903795 opens enrollment
NCT04903795 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which hEGFRvIII-CD3 (BRiTE) is the first listed.
NCT04903795 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04903795 about?
NCT04903795 is a clinical study titled "BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma". This Phase 1 study will assess the safety of a novel brain Bispecific T cell engager (BRiTE) in patients with newly diagnosed or recurrent World Health Organization (WHO) Grade 4 glioblastoma (GBM). Owing to its short half-life, the study drug, BRiTE, will be continuously infused intravenously (IV) ...
What is the current status of trial NCT04903795?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-08. Estimated completion is 2027-12.
What interventions are being tested in trial NCT04903795?
The interventions under investigation include: hEGFRvIII-CD3 (BRiTE) (DRUG).
Who is sponsoring clinical trial NCT04903795?
This trial is sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04903795's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia